entete

Toutes nos publications sur l'hypertension artérielle pulmonaire

2019

  1. F Tanguay V, Babin C, Giardetti G, Sohier-Poirier C, Ménard-Cholette V, Ranchoux B, Ruffenach G, Montani D, Bonnet S, Provencher S. Enhanced pulmonary artery radiodensity in Pulmonary Arterial Hypertension: A sign of early calcification? Am J Respir Crit Care Med. 2018 Dec 20. (Epub ahead of print)
  2. Humbert M, Guignabert C, Bonnet S, Dorfmüller P, Klinger JR, Nicolls MR, Olschewski AJ, Pullamsetti SS, Schermuly RT, Stenmark KR, Rabinovitch M. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019 Jan 24;53(1).
  3. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, Olsson KM, Peacock AJ, Pepke-Zaba J, Provencher S, Weissmann N, Seeger W. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019 Jan 24; 53(1) 

2018

  1. Bonnet S, Paulin R, Boucherat O. Small SeP or giant leap for Pulmonary Hypertension Research? Circulation. 2018 Aug 7;138(6):624-626
  2. Guay CA, Morin-Thibault LV, Bonnet S, Lacasse Y, Lambert C, Lega JC, Provencher S. Pulmonary hypertension-targeted therapies in heart failure: A systematic review and meta-analysis. Plos One. 2018 Oct 11;13(10):e0204610
  3. Couture EJ, Provencher S, Denault AY. Management of severe Pulmonary Hypertensive Disease for surgical and nonsurgical procedures. Int Anesthesiol Clin.Fall;56(4):e28-e55
  4. Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat O. Pulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets. Int J Biochem Cell Biol. 2018 Sep 3;104:9-13.
  5. Lajoie AC, Bonnet S, Lacasse Y, Lega JC, Provencher S. Interpreting risk reduction in clinical trials for pulmonary arterial hypertension. Eur Respir Rev. 2018 May 15;27(148).
  6. Provencher S, Archer SL, Ramirez FD, Hibbert B, Paulin R, Boucherat O, Lacasse Y, Bonnet S. Standards and methodological rigor in pulmonary arterial hypertension preclinical and translational research. Circulation Research. 2018 Mar 30;122(7):1021-1032
  7. Adao R, Mendes-Ferreira P, Santos-Ribeiro D, Maia-Rocha C, Pimentel L, Pinto C, Mulvaney EP, Reid HM, Kinsella BT, Potus F, Breuils-Bonnet S, Rademaker MT, Provencher S, Bonnet S, Leite-Moreira A, Bras-Silva C. Urocortin-2 improves right ventricular function in pulmonary arterial hypertension. Cardiovascular Research 2018 Mar 23.
  8. Kuebler WM, Bonnet S, Tabuchi A. Inflammation and autoimmunity in pulmonary hypertension- is there a role for endothelial adhesion molecules? Pulmonary Circulation 2018 Apr-Jun;8(2):2045893218757596
  9. Bonnet S and Boucherat O. The ROS controversy in hypoxic pulmonary hypertension revisited. Eur Respir J. 2018 Mar 8;51(3). pii:1800276
  10. Frump AL, Bonnet S, de Jesus Perez VA, Lahm T. The emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2018 Mar 1;314(3):L443-L460.
  11. Chen KH, Dasgupta A, Lin J, Potus F, Bonnet S, Iremonger J, Fu J, Mewburn J, Wu D, Dunhan-Snary K, Theilmann AL, Jing ZC, Hindmarch C, Ormiston ML, Lawrie A, Archer SL. Epigenetic dysregulation of the Drp1 binding partners MiD49 and MiD51 increases mitotic mitochondrial fission and promotes pulmonary arterial hypertension: mechanistic and therapeutic implications. Circulation 2018 Feb 5
  12. Boucherat O, Peterlini T, Bourgeois A, Nadeau V, Breuils-Bonnet S, Boilet-Molez S, Potus F, Meloche J, Chabot S, Lambert C, Tremblay E, Chae YC, Altieri DC, Sutendra G, Michelakis ED, Provencher S, Bonnet S. Mitochondrial HSP90 accumulation promotes vascular remodeling in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine. 2018 Feb 2.
  13. Ranchoux B, Harvey LD, Ayon RJ, Babicheva A, Bonnet S, Chan SY, Yuan JX, Perez VJ. Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscpae (2017 Grover Conference Series). Pulmonary Circulation. 2018 Jan-Mar;8(1):2045893217752912
  14. Nadeau V, Potus F, Boucherat O, Paradis R, Tremblay E, Iglarz M, Paulin R, Bonnet S, Provencher S. Dual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension. Pulmonary Circulation. 2018 Jan-Mar;8(1)
  15. Bourgeois A, Lambert C, Habbout K, Paquet-Marceau S, Trinh I, Breuils-Bonnet S, Paradis R, Nadeau V, Paulin R, Provencher S, Bonnet S, Boucherat O. FOXM1 promotes pulmonary smooth muscle cell expansion in pulmonary arterial hypertension. J Mol Med (Berl) 2018 Feb;96(2):223-235. 
  16. Zabini D, Granton E, Hu Y, Miranda MZ, Weichelt U, Breuils-Bonnet S, Bonnet S, Morrell NW, Connelly KA, Provencher S, Ghanim B, Klepetko W, Olschewski A, Kapus A, Kuebler WM. Loss of SMAD3 promotes vascular remodeling in pulmonary arterial hypertension via MRTF disinhibition. Am J Respir Crit Care Med. 2018 Jan 15;197(2):244-260.

2017

  1. Lajoie AC, Guay CA, Lega JC, Lauzière G, Simard S, Lambert C, Lacasse Y, Bonnet S, Provencher S. Trial duration and risk reduction in combination therapy trials for pulmonary arterial hypertension: A systematic review. Chest. 2017 Nov 23.
  2. Malenfant S, Brassard P, Paquette M, Le Blanc O, Chouinard A, Nadeau V, Allan PD, Tzeng YC, Simard S, Bonnet S, Provencher S. Compromised cerebrovascular regulation and cerebral oxygenation in pulmonary arterial hypertension. J Am Heart Assoc. 2017 Oct 12;6(10)
  3. Boucherat O, Provencher S, Bonnet S.Therapeutic Value of ASK1 in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2017 Sep 20
  4. Boucherat O, Chabot s, Paulin R, Trinh I, Bourgeois A, Potus F, Lampron MC, Lambert C, Breuils-Bonnet S, Nadeau V, Paradis R, Goncharova EA, Provencher S, Bonnet S. HDAC6: A novel histone deacetylase implicated in pulmonary arterial hypertension. Sci. Rep. 2017 Jul 3;7(1):4546
  5. Harel F, Langleben D, Provencher S, Fournier A, Finnerty V, Nguyen QT, Letourneau M, Levac X, Abikhzer G, Guimond J, Mansour A, Guertin MC, Dupuis J. Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principal trial. Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1136-1144.
  6. Lajoie AC, Bonnet S, Provencher S. Clinical trial research in focus: improving drug development ad trial design in pulmonary arterial hypertension. Lancet Respir Med. 2017 Jul;5(7):544-546
  7. Lajoie AC, Bonnet S, Provencher S. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulm Circ. 2017 Apr-Jun;7(2):312-325
  8. Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S, Bonnet S. The cancer theory of pulmonary arterial hypertension. Pulm. Circ. 2017 Apr-Jun;7(2):285-289
  9. Meloche J, Lampron MC, Nadeau V, Maltais M, Potus F, Lambert C, Tremblay E, Vitry G, Breuils-Bonnet S, Boucherat O, Charbonneau E, Provencher S, Paulin R, Bonnet S. Implication of inflammation and epigenetics Readers in Coronary Artery Remodeling in patients with pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2017 May 4. 
  10. Perros F, Humbert M, Nazzareno G, Simmoneau G, Bogaard HJ, de Man F, Antigny F, Provencher, Bonnet S, Galiè N, Humbert M.. The Use of beta-blockers in pulmonary hypertension. Circulation: Heart Failure. 2017 Apr;10(4)
  11. Hong Z, Chen K, Dasgupta A, Potus F, Dunham-Snary K, Bonnet S, Tian L, Fu J, Breuils-Bonnet S, Provencher S, Archer SL. miR-138 and miR-125 downregulate MCU, causing pulmonary arterial hypertension's cancer phenotype. Am J Resp Crit Care Med. 2017 Feb 15; 195(4):515-529 (Epub2016 Sep 20)
  12. Chun HJ, Bonnet S, Chan SY. Translating microRNA biology in pulmonary hypertension: it will take more than ''miR'' words. Am J Resp Crit Care Med.  2017 Jan;195(2):167-78 (Epub 2016 Sep 20)
  13. Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, Hassoun PM, Rabinovitch M, Nicolls MR, Humbert M. Translating research into improved patient care in pulmonary arterial hypertension. Am J Resp Crit Care Med. 2017 Mar1;195(5):583-85 (Epub 2016 Sep 20)

2016


  1. Boucherat O, Bonnet S and Paulin R. The HIPPO-thesis of pulmonary HYPERtension. Am J Resp Crit Care Med. 2016 Oct 1;194(7):787-9
  2. Hong Z, Chen K, Dasgupta A, Potus F, Dunham-Snary K, Bonnet S, Tian L, Fu J, Breuils-Bonnet S, Provencher S, Archer SL. miR-138 and miR-125 downregulate MCU, causing pulmonary arterial hypertension's cancer phenotype. Am J Resp Crit Care Med. 2016 Sep 20. (Epub ahead of print)
  3. Chun HJ, Bonnet S, Chan SY. Translating microRNA biology in pulmonary hypertension: it will take more than ''miR'' words. Am J Resp Crit Care Med. 2016 Sep 20 (Epub ahead of print)
  4. Bonnet S, Provencher S, Guignabert C, Perros F, Boucherat O, Schermuly RT, Hassoun PM, Rabinovitch M, Nicolls MR, Humbert M. Translating research into improved patient care in pulmonary arterial hypertension. Am J Resp Crit Care Med. 2016 Sep 20 (Epub ahead of print)
  5. Ranchoux B*, Meloche J*, Paulin R, Boucherat O, Provencher S, Bonnet S. DNA damage and pulmonary hypertension. International Journal of Molecular Sciences. 2016 Jun 22;17(6).
  6. Bonnet S and Provencher S. Shear stress maladaptation in pulmonary arterial hypertension: an ageless concept. Am J Resp Crit Care Med.2016 Jun 15;193(12):1331-2
  7. Boucherat O, Bonnet S. MicroRNA signature of End-Stage idiopathic pulmonary arterial hypertension: Clinical correlations and regulation of WNT signaling. Journal of Molecular Medicine (Berlin). 2016 Aug;94(8):849-51
  8. Ruffenach*, Chabot S*, Tanguay VF, Courboulin A, Boucherat O, Potus f, Meloche J, Pflieger A, Breuils-Bonnet S, Nadeau V, Paradis R, Girerd B, Hautefort A, Montani D, Fadel E, Dorfmuller P, Humbert M, Perros F, Paulin R, Provencher S, Bonnet S. RUNX2 in proliferative and calcified vascular lesions seen in pulmonary arterial hypertension. Am J Resp Crit Care Med. 2016 May 5 (Epub ahead of print)
  9. Lajoie AC, Lauzière G, Lega JC, Lacasse Y, Martin S, Simard S, Bonnet S, Provencher S. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respi Med. 2016 Feb 26. (Epub ahead of print)
  10. Antigny F, Hautefort A, Meloche J, Belacel-Ouari M, Manoury B, Rucker-Martin C, Péchoux C, Potus F, Nadeau V, Tremblay E, Ruffenach G, Bourgeois A, Dorfmuller P, Breuils-Bonnet S, Fadel E, Ranchou B, Jourdon P, Girerd B, Montani D, Provencher S, Bonnet S, Simmoneau G, Humbert M, Perros F. Potassium-channel subfamily K-member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension. Circulation. 2016 Feb 24 (Epub ahead of print)
  11. Courboulin A, Ranchoux B, Cohen-Kaminsky S, Perros F, Bonnet S. MicroRNA networks in pulmonary arterial hypertension: share mechanisms with cancer? Curr Opin Oncol. 2016 Jan;28(1):72-82

2015


  1. Boucherat O, Potus F, Bonnet S. microRNA and Pulmonary Hypertension. Adv Exp Med Biol. 2015;888:237-52
  2. Perros F, Bonnet S. Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world. Am J Respir Crit Care Med. 2015 Oct 1;192(7):777-9
  3. Fabrice A, Benoît R, Valérie N, Lau E, Sébastien B, Frédéric P. A simple method to assess in vivo proliferation in lung vasculature with EdU: The case of MMC-induced PVOD in rat. Anal Cell Pathol (Amst). 2015;2015:326385
  4. Boucherat O, Chabot S, Antigny F, Perros F, Provencher S, Bonnet S. Potassium channels in pulmonary arterial hypertension. Eur Respir J. 2015 Sep 4. Review
  5. Meloche J, Potus F, Vaillancourt M, Bourgeois A, Johnson IH, Deschamps L, Chabot S, Ruffenach GN, Henry S, Breuils-Bonnet S, Tremblay È, Nadeau V, Lambert CM, Paradis R, Provencher S, Bonnet S. Bromodomain Containing Protein-4: The epigenetic origin of pulmonary arterial hypertension. Circ Res. 2015 Aug 28;117(6):525-35.
  6. Potus F, Ruffenach G, Dahou A, Thebault C, Breuils-Bonnet S, Tremblay È, Nadeau V, Paradis R, Graydon C, Wong R, Johnson I, Paulin R, Lajoie AC, Perron J, Charbonneau E, Joubert P, Pibarot P, Michelakis ED, Provencher S, Bonnet S. Downregulation of miR-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation. 2015 Sep 8;132(10):932-43.
  7. Meloche J, Le Guen M, Potus F, Vinck J, Ranchoux B, Johnson I, Antigny F, Tremblay E, breuils-Bonnet S, Perros F, Provencher S, Bonnet S. MiR-223 reverses experimental pulmonary arterial hypertension. Am J Physiol Cell Physiol. 2015 June 17.
  8. Courboulin A, Kang C, Baillard O, Bonnet S, Bonnet P. Increasing pulmonary artery pulsatile flow improves hypoxic pulmonary hypertension in piglets. J Vis Exp. 2015 May 11;(99). Vidéo
  9. Malenfant S, Potus F, Mainguy V, Leblanc È, Malenfant M, Ribeiro F, Saey D, Maltais F, Bonnet S, Provencher S. Impaired skeletal muscle oxygenation and exercise tolerance in pulmonary hypertension. Med Sci Sports Exerc. 2015 May 12
  10. Sutendra G, Bonnet S. The iron paradigm of pulmonary arterial hypertension: popeye knows best. Circ Res. 2015 May 8;116(10):1636-8.
  11. Boucherat O, Bonnet S. NOGGIN: a new therapeutic target for PH? Focus on “Noggin inhibits hypoxia-induced proliferation by targeting store-operated calcium entry and TRPC channels”. Am J Physiol Cell Physiol. 2015 April 1.
  12. Vaillancourt M, Ruffenach G, Meloche J, Bonnet S. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension. Can J Cardiol. 2015 Apr;31(4):407-15. Review
  13. Malenfant S, Potus F, Fournier F, Breuils-Bonnet S, Pflieger A, Bourassa S, Tremblay È, Nehmé B, Droit A, Bonnet S, Provencher S. Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension. J Mol Med (Berl). 2015 May;93(5):573-84.
  14. Provencher S, Granton JT. Current treatment approaches to pulmonary arterial hypertension. Can J Cardiol. 2015 Apr;31(4):460-77.
  15. Provencher S, Paruchuru P, Spezzi A, Waterhouse B, Gomberg-Maitland M, on behalf of the pH12 Flolan reformulation study group. Quality of Life, Safety and Efficacy profile of thermostable Flolan in pulmonary arterial hypertension. PLOS ONE. 2015 Mar 20;10(3).
  16. Paulin R, Sutendra G, Gurtu V, Dromparis P, Haromy AS, Provencher S, Bonnet S, Michelakis E. A miR-208-Mef2 axis drives the de-compensation of right ventricular function in Pulmonary Hypertension. Circ Res. 2015;116(1):56-69.

2014

  1. Paulin R, Dromparis P, Sutendra G, Gurtu V, Zervopoulos S, Bowers L, Haromy A, Webster L, Provencher S, Bonnet S, Michelakis ED. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans. Cell Metab. 2014 Nov 4;20(5):827-39.
  2. Malenfant S, Potus F, Fournier F, Breuils-Bonnet S, Pflieger A, Bourassa S, Tremblay È, Nehmé B, Droit A, Bonnet S, Provencher S.  Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension. J Mol Med (Berl) 2014 Dec 30; [Epub ahead of print]
  3. Sharma S, Umar S, Potus F, Iorga A, Wong G, Meriwether D, Breuils-Bonnet S, Mai D, Navab K, Ross D, Navab M, Provencher S, Fogelman AM, Bonnet S, Reddy ST, Eghbali M. Apolipoprotein A-I Mimetic Peptide 4F Rescues Pulmonary Hypertension by Inducing MicroRNA-193-3p. Circulation 2014; 130(9): 776-85.
  4. Potus F, Malenfant S, Graydon C, Mainguy V, Tremblay E, Breuils-Bonnet S, Ribeiro F, Porlier A, Maltais F, Bonnet S, Provencher S. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med 2014; 190(3): 318-28.
  5. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulous S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C,  Michelakis ED, Provencher S, Bonnet S. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014: 129(7): 786-97. 
    Titulaire du "Sir John Vane Award" pour la meilleure publication récente en lien avec les maladies vasculaires pulmonaires.
  6. Paulin R, Meloche J, Courboulin A, Lambert C, Haromy A, Courchesne A, Bonnet P, Provencher S, Michelakis ED, Bonnet S. Targeting cell motility in pulmonary arterial hypertension. Eur Respir J. 2014; 43(2): 531-44.
  7. Chaouat A, Sitbon O, Mercy M, Ponçot-Mongars R, Provencher S, Guillaumot A, Gomez E, Selton-Suty C, Malvestio P, Regent D, Paris C, Hervé P, Chabot F. Pronostic value of exercise cardiac index in idiopathic, familial and anorexigen-associated pulmonary arterial hypertension. Eur Respir J 2014; 44(3): 704-13.
  8. Meloche J, Pflieger A, Vaillancourt M, Graydon C, Provencher S, Bonnet S. miRNAs in PAH: biomarker, therapeutic target or both? Drug Discovery Today 2014; 19(8): 1264-9.
  9. Potus F, Graydon C, Provencher S, Bonnet S. Vascular remodeling process in pulmonary arterial hypertension with focus on miR-204 and miR126. Pulm Circ 2014; 4(2): 175-84.
  10. Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S. Effect of pulmonary arterial hypertension specific therapies on health-related quality of life: a systematic review. Chest 2014; 146(3):1-23.
  11. Mainguy V, Malenfant S, Neyron AS, Saey D, Maltais F, Bonnet S, Provencher S. Alternatives to the six-minute walk test in pulmonary arterial hypertension. PlosOne 2014; 9(8): e103626.

2013

  1. Malenfant S*, Neyron AS*, Paulin R, Potus F*, Meloche J, Provencher S, Bonnet S. Signal transduction pathways in the development of pulmonary arterial hypertension. Pulm Circ. 2013 Apr;3(2):278-293.
  2. Chemla D, Castelain V, Hoette S, Creuze N, Provencher S, Zhu K, Humbert M, Herve P. Strong linear relationship between heart rate and mean pulmonary artery pressure in exercising patients with severe precapillary pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2013; 305: H769-H777. 
  3. Vonk Noordegraaf A, Haddad F, Chin KM, Forfia Pr, Dawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, Torbicki A, Voelkel N, Hassoun PM. Right Heart Adaptation to Pulmonary Arterial Hypertension: Physiology and Pathobiology. J Am Coll Cardiol 2013; 62(25 suppl): D22-33.
  4. Mainguy V*, Malenfant S*, Neyron AS*, Bonnet S, Maltais F, Saey D, Provencher S. Repeatability and responsiveness of exercise tests in pulmonary arterial hypertension. Eur Respir J. 2013 Aug;42(2):425-34 (Corresponding and senior author)
  5. Provencher S, Mainguy V*, Simon M, Martel M. Physiopathologie des maladies vasculaires pulmonaires. Presses de l'Université Laval 2013 (corresponding author)
  6. Meloche J*, Renard S*, Provencher S, Bonnet S. Anti-inflammatory and Immunosuppressive Agents in PAH. In Pharmacotherapy of Pulmonary Hypertension Handbook of Experimental Pharmacology 2013;218:437-476. Publisher Springer-Verlag; Editors Marc Humbert, Oleg V Evgenov, Johannes-Peter Stasch. (co-senior author).
  7. Meloche J, Paulin R, Provencher S, Bonnet S. Therapeutic potential of microRNA modulation in pulmonary arterial hypertension. Current Vascular Pharmacology 2013; May 13. [Epub ahead of print].
  8. Renard S, Paulin R, Breuils-Bonnet S, Simard S, Pivarot P, Bonnet S, Provencher S. Pim-1: a new biomarker in pulmonary arterial hypertension. Pulmonary Circulation 2013; 3(1): 74-81.
  9. Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay E, Biardel S, Racine C, Couture C, Bonnet P, Majka SM, Deshaies Y, Picard F, Provencher S, Bonnet S. Critical Role of the Advanced Glycation Endproducts Receptor in Pulmonary Arterial Hypertension Ethiology. J Am Heart Assoc 2013; 2:e005157 doi: 10.1161/JAHA.112.00515
  10. Malenfant S, Margaillan G, Loehr J, Bonnet S, Provencher S. The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to near future. Expert Review of Respiratory Medicine 2013; 7(1): 1-13.
  11. Provencher S, Renard S, Rival G. Exploration pulmonaire par cathétérisme droit. EMC-Pneumologie 2013; 10(1): 1-10. [Article 6-000-F-20].

2012

  1. Mainguy V, Malenfant S, Neyron AS, Bonnet S, Maltais F, Saey D, Provencher S. Repeatability and responsiveness of exercise tests in pulmonary arterial hypertension. Eur Respir J 2012; [Epub ahead of print]
  2. Provencher S, Mainguy V. Exercise testing in Pulmonary Arterial Hypertension. Progress in Respiratory Research : Pulmonary Vascular disorders. Krager 2012, Vol. 41, pp 37-47. Editor CT Bolliger. ISBN 978-3-8055-9914-4.
  3. Provencher S, Chemla D, Hervé P. Hémodynamique de repos et d’effort dans l’hypertension artérielle pulmonaire / Resting and exercise hemodynamics in pulmonary arterial hypertension. La Presse Médicale 2011;40 :1528-1538.
  4. Paulin R, Meloche J, Bonnet S. STAT3 signaling in pulmonary arterial hypertension. JAK-STAT 2012; 1(4): 1-11.
  5. Courboulin A, Barrier M, Perreault T, Bonnet P, Tremblay VL, Paulin R, Tremblay E, Lambert C, Jacob MH, Bonnet SN, Provencher S, Bonnet S. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J. 2012; 40:618-29.
  6. Barrier M, Meloche J, Jacob MH, Courboulin A, Provencher S, Bonnet S. Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension. Cell Mol Life Sci. 2012; 69:2805-31.
  7. Provencher S, Bonnet S. Pulmonary arterial hypertension research: Why does it take so long? How can I contribute? Connections 2012; 3(2): 26-7.

2011

  1. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, Côté J, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation. 2011;123(11):1205-15.
  2. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, Simard MJ, Bonnet S. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011;208(3):535-48.
  3. Sutendra G, Dromparis P, Bonnet S, HaromyA, McMurtry MS, Bleackley C, Michelakis E. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) 2011; 89(8) :771-83.
  4. Sutendra G; Bonnet S et al. A novel role of reticulon-4 (Nogo) in the mitochondria-endoplasmic reticulum unit and the pathogenesis of pulmonary arterial hypertension. Sci Transl Med 2011; 3(88) : 88ra55.
  5. Roxane Paulin, Marjorie Barrier and Sebastien Bonnet. New Therapeutics for pulmonary arterial hypertension: do gene therapies have translational values? Future Science. Clin Invest 2011;1(3):363-6..
  6. Paulin Roxane, Eric Dumas De La Roque, and Sebastien Bonnet. DHEA and vascular health and fonctions. DHEA (dehydroepiandrosterone) in Human Health and Aging, DHEA chapters from Dr. Ronald Watson. editor: Taylor and Francis Group 2011. ISBN 9781439838839.
  7. Courboulin A, Tremblay VL, Barrier M, Meloche J, Jacob MH, Chapolard M, Bisserier M, Paulin R, Lambert C, Provencher S, Bonnet S. Krüppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res 2011; 12(1):128.
  8. Mainguy V, Provencher S, Maltais F, Malenfant S, Saey D. Assessment of Daily Life Physical activities in Pulmonary Arterial Hypertension. Plos One 2011;6(11):e27993.
  9. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Sassouk N, Coté J, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators of transcription-3/Pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 2011; 123(11): 1205-1215.
  10. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perrault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, Simard MJ, Bonnet S. A critical role of microRNAs in human pulmonary arterial hypertension. miR-204: a novel therapeutic target. J Exp Med 2011;208(3):535-48.
  11. Provencher S, Chemla D, Hervé P. Hémodynamique de repos et d’effort dans l’hypertension artérielle pulmonaire / Resting and exercise hemodynamics in pulmonary arterial hypertension. La Presse Médicale 2011;40 (suppl 1) :1S28-38. (corresponding author).
  12. Belmokhtar K, Bourguignon T, Worou ME, Khamis G, Bonnet P, Domenech J, and Eder V. Regeneration of three layers vascular wall by using BMP2-treated MSC involving HIF-1alpha and Id1 expressions through JAK/STAT pathways. Stem cell reviews 7: 847-859; 2011

2010

  1. Lambert CM, Roy M, Meloche J, Robitaille GA, Agharazii M, Richard DE, Bonnet S. Tumor necrosis factor inhibitors as novel therapeutic tools for vascular remodeling diseases. Am J Physiol Heart Circ Physiol. 2010;299(4):H995-1001.
  2. Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD, Dyck JR, Michelakis ED. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med. 2010;2(44):44ra58.
  3. Lambert CM, Roy M, Robitaille GA, Richard DE, Bonnet S. HIF-1 inhibition decreases systemic vascular remodelling diseases by promoting apoptosis through a hexokinase 2-dependent mechanism. Cardiovasc Res 2010; 88(1):196-204.
  4. Dumas de la Roque E, Savineau JP, Bonnet S. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol Ther 2010;126(2):186-99.
  5. Mehta S, Helmersen D, Provencher S, Hirani N, Rubens FD, De Perrot M, Blostein M, Boutet K, Chandy G, Dennie C, Granton J, Hernandez P, Hirsch AM, Laframboise K, Levy RD, Lien D, Martel S, Shoemaker G, Swiston J, Weinkauf J; for the Canadian Thoracic Society Pulmonary Vascular Disease - CTEPH CPG Development Committee; and the Canadian Thoracic Society Canadian Respiratory Guidelines Committee. Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: A clinical practice guideline. Can Respir J. 2010;17(6):301-334.  
  6. Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M, Provencher S. Effects of a rehabilitation program on skeletal muscle function in idiopathic pulmonary arterial hypertension. J Cardiopulm Rehabil Prev 2010;30(5): 319-23.
  7. Mainguy V, Maltais F, Saey D, Gagnon P, Martel S, Simon M, Provencher S. Peripheral Muscle Dysfunction in Idiopathic Pulmonary Arterial Hypertension. Thorax 2010; 65(2) : 113-117.

2009

  1. Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson KO, Nagendran J, Haromy A, Dyck JR, Michelakis ED. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation 2009; 120(13):1231-40.
  2. McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galié N, Gibbs JSR, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W. End Points and Clinical Trial Design in PAH. J Am Coll Cardiol 2009; 54(1): S97-107.
  3. Grünig E, Weissmann S, Ehlken N,Fijalkowska A, Fischer C, Fourme T, Galié N, Ghofrani A, Harrison RE, Huez S, Humbert M, Janssen B, Kober J, Koehler R, Machado RD, Mereles D, Naeije R, Olschewski H, Provencher S, Reichenberger F, Retailleau K, Rocchi G, Simonneau G, Torbicki A, Trembath R, Seeger W. Stress-Doppler-echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation 2009;119:1747-1757.
  4. Chemla D, Castelain V, Provencher S, Humbert M, Simonneau G, Hervé P. Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. Chest 2009;135(3):760-8.
  5. Lega JC, Lacasse Y, Lakhal L, Provencher S. Natriuetic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax 2009; 64 : 869-875
  6. Van Haaften T, Akabutu J, Bonnet S, Eaton F, Hashimoto K, Kirby B, Haromy A, Michelakis ED, Archer SL, Thebaud B. Intratracheal Mesenchymal Stem Cells Attenuates Oxygen-induced Lung Injury. Am J Respir Crit Care Med 2009; 180(11):1131-42.

2008

  1. Provencher S, Hervé P, Sitbon O, Humbert M, Simonneau G, Chemla D. Changes in Exercise hemodynamics during treatment in Pulmonary Arterial Hypertension. Eur Respir J 2008; 32: 393-398

  2. Bonnet P, Awede B, Rochefort GY, Mirza A, Lermusiaux P, Domenech J, and Eder V. Electrophysiological maturation of rat mesenchymal stem cells after induction of vascular smooth muscle cell differentiation in vitro. Stem cells and development 17: 1131-1140, 2008

     

2007

  1. Koonen DP, Febbraio M, Bonnet S, Nagendran J, Young ME, Michelakis ED, Dyck JR. Increased Glucose Oxidation Attenuates Age-dependent Decreases in Cardiac Performance and Prevents Cardiac Hypertrophy. Circulation. 2007;116(19):2139-47.
  2. Bonnet S, Archer SL. Potassium Channel Diversity in the Pulmonary Arteries and Pulmonary Veins: Implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension. Pharmacol Ther. 2007;115(1):56-69.
  3. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED.. The nuclear factor of activated T-cells in Pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A. 2007;104(27):11418-23.
  4. McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL.. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin (RATS) study. Am J Physiol Lung Cell Mol Physiol 2007;293 :L233-40.
  5. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED.. A Mitochondria- Plasmamembrane K+ Channel Axis as a novel therapeutic target for cancer. Cancer Cell 2007;11(1):37-51).
© 2012 Universit� Laval. Tous droits r�serv�s